Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

GSK gets EU approval to sell blood cancer treatment Omijara

(Sharecast News) - Biopharma giant GSK has been given the green light by European regulators to sell Omjjara, its treatment for patients with a rare type of blood cancer. GSK announced on Monday that Omjjara, its brand name for momelotinib, has been granted marketing authorisation by the European Commission, giving the company permission to market the drug and make it available to patients and healthcare professionals across the EU and EEA-EFTA states of Iceland, Liechtenstein and Norway.

Omjjara is the first medicine in the continent specifically indicated for treating an enlarged spleen (known as splenomegaly) which is common with patients suffering from blood cancer myelofibrosis, specifically for those with moderate to severe anaemia.

GSK said that myelofibrosis affects an estimated one in 10,000 people in the EU, with nearly all patients likely to develop anaemia over the course of the disease.

"The challenges of living with myelofibrosis can be burdensome, and symptomatic patients can experience spleen enlargement, fatigue, night sweats and bone pain," said Nina Mojas, the senior vice president of GSK's Oncology Global Product Strategy unit.

"Until now, there have been no options specifically indicated to treat these symptoms in patients who also experience anaemia. The authorisation of Omjjara brings a new treatment option with a differentiated mechanism of action to these patients in the EU."

In a separate statement, GSK also said the the European Medicines Agency has accepted its Arexvy drug, developed for the prevention of respiratory syncytial virus (RSV) disease, for regulatory review.

The application follows positive results from a Phase III study showing immune response and an "acceptable tolerability profile" in adults aged 50-59 at increased risk. GSK said it is the first company to file for regulatory approval to extend RSV vaccination to adults aged 50-59 at increased risk.

Share this article

Related Sharecast Articles

Bluejay to broaden into helium and industrial gases
(Sharecast News) - Bluejay Mining announced a strategic decision to broaden its corporate scope, expanding into the exploration and development of helium, industrial gases, and hydrocarbons, on Friday.
Man Group's Q1 miss was temporary "roadbump", says Jefferies
(Sharecast News) - Shares in Man Group dropped on Friday after the investment management firm reported unexpected net outflows in the first quarter, but that didn't deter Jefferies from reiterating its 'buy' rating for the stock.
Vector Capital reports robust year-end financial position
(Sharecast News) - Commercial lender Vector Capital reported continued growth in shareholders' equity while maintaining dividends and implementing prudent bad debt provision policies in its full-year results on Friday.
Quadrise posts progress with Utah partner Valkor
(Sharecast News) - Quadrise updated the market on its collaboration with Valkor Technologies in Utah on Friday, targeting the supply of low sulphur 'MSAR' and 'bioMSAR' to the marine and power sector.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.